AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance-Reference-Cited by-同舟云学术

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Published:2009-11 Issue:5 Volume:16 Page:401-412
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

O'Hare Thomas,Shakespeare William C.,Zhu Xiaotian,Eide Christopher A.,Rivera Victor M.,Wang Frank,Adrian Lauren T.,Zhou Tianjun,Huang Wei-Sheng,Xu Qihong,Metcalf Chester A.,Tyner Jeffrey W.,Loriaux Marc M.,Corbin Amie S.,Wardwell Scott,Ning Yaoyu,Keats Jeffrey A.,Wang Yihan,Sundaramoorthi Raji,Thomas Mathew,Zhou Dong,Snodgrass Joseph,Commodore Lois,Sawyer Tomi K.,Dalgarno David C.,Deininger Michael W.N.,Druker Brian J.,Clackson Tim

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference29 articles.

1. Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations;Bradeen;Blood,2006

2. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance;Burgess;Proc. Natl. Acad. Sci. USA,2005

3. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors;Cortes;Blood,2007

4. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N. Engl. J. Med.,2006

5. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N. Engl. J. Med.,2001

Cited by 1017 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

2. In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I;Molecules;2024-09-08

3. Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia;Blood;2024-09-05

4. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

5. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02